Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

BioTime Subsidiary AgeX Therapeutics Appoints Aubrey de Grey, Ph.D. as VP of New Technology Discovery

Business Wire July 13, 2017

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioTime, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire June 26, 2017

Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences

PR Newswire June 19, 2017

Biotime Expands & Advances Ophthalmology Portfolio

Business Wire June 19, 2017

BioTime’s Renevia® Achieves Primary Endpoint in European Pivotal Trial

Business Wire June 14, 2017

BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial

Business Wire June 8, 2017

How These Biotech Stocks are Faring? -- Idera Pharma, BioTime, RXi Pharma, and Tenax Therapeutics

PR Newswire May 24, 2017

BioTime Co-CEO Dr. Michael West to Deliver Presentation as Part of Biotech Panel at Mauldin Economics’ Strategic Investment Conference on May 24

Business Wire May 23, 2017

BioTime to Present at 16th National Life Sciences and Biotechnology Week (MIXiii BIOMED)

Business Wire May 23, 2017

Regenerative Technology Innovations in the Medical Market

PR Newswire April 4, 2017

BioTime Announces Issuance of 31 New Patents to Strengthen its Patent Portfolio in Regenerative Medicine

Business Wire August 15, 2016

BioTime, Inc. Reports Second Quarter Results and Recent Corporate Accomplishments

Business Wire August 9, 2016

BioTime, Inc. to Report Second Quarter Results on August 9, 2016

Business Wire July 27, 2016

BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option

Business Wire July 5, 2016

BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering

Business Wire June 29, 2016

BioTime, Inc. Announces Closing of Public Offering of Common Stock

Business Wire June 21, 2016

BioTime, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire June 16, 2016

BioTime, Inc. Announces Proposed Public Offering of Common Stock

Business Wire June 15, 2016

BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD

Business Wire June 13, 2016

BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

Business Wire June 10, 2016